Last reviewed · How we verify
HUC2-565-B, HUC2-565-A and HUC2-565-B
HUC2-565-B, HUC2-565-A and HUC2-565-B is a Small molecule drug developed by Huons Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | HUC2-565-B, HUC2-565-A and HUC2-565-B |
|---|---|
| Sponsor | Huons Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HUC2-565-B, HUC2-565-A and HUC2-565-B CI brief — competitive landscape report
- HUC2-565-B, HUC2-565-A and HUC2-565-B updates RSS · CI watch RSS
- Huons Co., Ltd. portfolio CI
Frequently asked questions about HUC2-565-B, HUC2-565-A and HUC2-565-B
What is HUC2-565-B, HUC2-565-A and HUC2-565-B?
HUC2-565-B, HUC2-565-A and HUC2-565-B is a Small molecule drug developed by Huons Co., Ltd..
Who makes HUC2-565-B, HUC2-565-A and HUC2-565-B?
HUC2-565-B, HUC2-565-A and HUC2-565-B is developed by Huons Co., Ltd. (see full Huons Co., Ltd. pipeline at /company/huons-co-ltd).
What development phase is HUC2-565-B, HUC2-565-A and HUC2-565-B in?
HUC2-565-B, HUC2-565-A and HUC2-565-B is in Phase 1.